Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Fineline Cube

    • Home
    • Fineline Cube
    • Page 677
Drug Medical Device

Shanghai Roche Pharmaceuticals Launches Erlotinib for Advanced Non-Small Cell Lung Cancer in China

Fineline Cube Apr 4, 2007

Shanghai Roche Pharmaceuticals Ltd. made headlines in March with the launch of its lung cancer...

Posts pagination

1 … 676 677

Recent updates

  • AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use
  • Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery
  • Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment
  • CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus
  • AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use

Others

Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery

Company Drug

Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment

Others

CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.